Clinical Trials Logo
  1. Home
  2. Graft Versus Host Disease
  3. NCT01927120

In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis

Graft-Versus-Host-Disease Clinical Trial

Official title:
In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis With IL-2, Sirolimus, and Tacrolimus Following Allogeneic Hematopoietic Cell Transplantation

Clinical Trial Summary

IL-2 add-back post allogeneic hematopoietic stem cell transplant (HSCT), combined with Sirolimus (SIR), Tacrolimus (TAC) will optimize Treg reconstitution and prevent graft versus host disease (GVHD).

Clinical Trial Description

1) Determine if a GVHD prophylaxis regimen of IL-2/SIR/TAC enhances in vivo Treg differentiation and growth; 2) Study the safety and effects of IL-2/SIR/TAC on the incidence of acute and chronic GVHD; 3) Evaluate the influence of dual IL-2 supplementation and mammalian target of rapamycin (mTOR) inhibition on T cell-specific signaling pathways and the polarization of emerging T helper cells. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01927120
Study type Interventional
Source H. Lee Moffitt Cancer Center and Research Institute
Contact
Status Active, not recruiting
Phase Phase 2
Start date March 25, 2014
Completion date January 2018
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04792580 - The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease Early Phase 1
Not yet recruiting NCT05969743 - Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease Phase 2
Active, not recruiting NCT04669210 - PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT Phase 2
Completed NCT04014790 - RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation Phase 2
Recruiting NCT06008808 - Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation Phase 1
Recruiting NCT03395860 - Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCT Phase 2
Completed NCT03207958 - Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation Phase 1
Completed NCT03414645 - Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease Phase 1/Phase 2
Completed NCT03846479 - Itacitinib for Low Risk GVHD Phase 2
Recruiting NCT06321003 - SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography
Not yet recruiting NCT06279585 - Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD N/A
Suspended NCT05617625 - CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome Phase 2
Not yet recruiting NCT06392711 - Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia Phase 1
Withdrawn NCT00723593 - Natural History and Pathophysiology of Gastrointestinal Graft-versus-Host Disease N/A
Recruiting NCT03148197 - Changes in the Gut Microbiota of Patients Undergoing Allogeneic Stem Cell Transplantation (COLLECT) N/A
Recruiting NCT03456817 - HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis Phase 2
Completed NCT00827398 - Treatment of Steroid Resistant GVHD by Infusion MSC Phase 1/Phase 2
Recruiting NCT03842696 - Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation Phase 1/Phase 2
Completed NCT03605927 - CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease Phase 1
Recruiting NCT04688021 - A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT. Phase 2